In vitro, the EGFR inhibitor erlotinib/Tarceva (ERLO), which is approved for the treatment of lung cancers harboring specific mutations in EGFR, strongly inhibited proliferation of cells derived from BVZ-resistant tumors 9. Here, EGFR is linked to lung carcinoma.